Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$32.12 USD
+0.08 (0.25%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $32.03 -0.09 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARS 32.12 +0.08(0.25%)
Will TARS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Other News for TARS
Commit To Buy Tarsus Pharmaceuticals At $15, Earn 7.6% Annualized Using Options
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus refinances existing debt with $200M financing commitment
Tarsus Pharmaceuticals Secures $75M Loan for Growth and Debt Repayment